Other GLP-1 receptor agonists include semaglutide (Wegovy for weight management, Ozempic for diabetes) and liraglutide (Saxenda for weight management, Victoza for diabetes), with semaglutide 2.4 mg demonstrating greater average weight loss than liraglutide 3.0 mg in clinical trials
The American Association of Clinical Endocrinology (AACE) has noted in its 2023 guidelines that "compounded peptides used off-label should be treated as investigational agents requiring the same monitoring rigor as clinical-trial protocols" [11]
As a result, people with a family or personal history of thyroid cancer or tumors may not be good candidates for GLP-1 treatment
Both require caution because much of the evidence is preclinical or early-stage, product quality can vary, and legal or compounding rules can change
Agmatine Sulfate: Thnh phn ny c ngun gc t L-Arginine
Oxidant body function increases following SLU-PP-332 use